Cargando…

Prognostic and Clinical Value of Interleukin 6 and CD45(+)CD14(+) Inflammatory Cells with PD-L1(+)/PD-L2(+) Expression in Patients with Different Manifestation of Ovarian Cancer

Ovarian cancer (OC) is one of the deadliest gynecological cancers. Recent studies suggest a crucial role of inflammatory immune system cells in the progression and metastasis of OC. The understanding of inflammatory mechanisms is pivotal for the selection of a biomarker that allows the differentiati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wertel, Iwona, Suszczyk, Dorota, Pawłowska, Anna, Bilska, Monika, Chudzik, Agata, Skiba, Wiktoria, Paduch, Roman, Kotarski, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545411/ https://www.ncbi.nlm.nih.gov/pubmed/33062717 http://dx.doi.org/10.1155/2020/1715064

Ejemplares similares

Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients
por: Pawłowska, Anna, et al.
Publicado: (2021)

The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients
por: Pawłowska, Anna, et al.
Publicado: (2022)

Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis
por: Suszczyk, Dorota, et al.
Publicado: (2022)

Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients
por: Pawłowska, Anna, et al.
Publicado: (2020)

The Role of Myeloid-Derived Suppressor Cells (MDSCs) in the Development and/or Progression of Endometriosis-State of the Art
por: Suszczyk, Dorota, et al.
Publicado: (2021)

Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy
por: Bilska, Monika, et al.
Publicado: (2020)

The Role of the Adipokine Resistin in the Pathogenesis and Progression of Epithelial Ovarian Cancer
por: Parafiniuk, Klaudia, et al.
Publicado: (2022)

Clinical Significance of Tie-2-Expressing Monocytes/Macrophages and Angiopoietins in the Progression of Ovarian Cancer—State-of-the-Art
por: Skiba, Wiktoria, et al.
Publicado: (2022)

Expression of Gal-9 on Dendritic Cells and Soluble Forms of TIM-3/Gal-9 in Patients Suffering from Endometriosis
por: Suszczyk, Dorota, et al.
Publicado: (2023)

γδ T Lymphocytes as a Double-Edged Sword—State of the Art in Gynecological Diseases
por: Pawłowska, Anna, et al.
Publicado: (2022)

The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters
por: Walankiewicz, Monika, et al.
Publicado: (2018)

Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry
por: Kwiecień, Iwona, et al.
Publicado: (2021)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
por: Wu, Si-Pei, et al.
Publicado: (2015)

Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status
por: Camy, Florian, et al.
Publicado: (2020)

Accumulation of CD5(+)CD19(+) B lymphocytes expressing PD-1 and PD-1L in hypertrophied pharyngeal tonsils
por: Wlasiuk, Paulina, et al.
Publicado: (2015)

CD8(+)PD-1(+) to CD4(+)PD-1(+) ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
por: Duchemann, Boris, et al.
Publicado: (2022)

Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients
por: Geng, Ruixuan, et al.
Publicado: (2023)

Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80
por: Cassady, Kaniel, et al.
Publicado: (2018)

Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
por: Zhang, Chaoxu, et al.
Publicado: (2020)

Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma
por: Ma, Ke, et al.
Publicado: (2020)

PD-1/PD-L1 Control of Antigen-Specifically Activated CD4 T-Cells of Neonates
por: Majer, Christiane, et al.
Publicado: (2023)

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
por: Banchereau, Romain, et al.
Publicado: (2021)

Circulating Exhausted PD-1(+)CD39(+) Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade
por: Martinez-Gomez, Carlos, et al.
Publicado: (2022)

Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors
por: Pawłowska, Anna, et al.
Publicado: (2023)

The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes
por: Kuszczak, Bartłomiej, et al.
Publicado: (2023)

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression
por: Lin, Ziying, et al.
Publicado: (2019)

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
por: Zuazo, Miren, et al.
Publicado: (2020)

PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas
por: Xie, Wei, et al.
Publicado: (2022)

Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA
por: Zhang, Wenxin, et al.
Publicado: (2023)

Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1
por: Okła, Karolina, et al.
Publicado: (2020)

Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritis
por: Bartosińska, Joanna, et al.
Publicado: (2018)

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages
por: Lai, Chun-Yi, et al.
Publicado: (2021)

PD-1(+)CD8(+) T Cells Proximal to PD-L1(+)CD68(+) Macrophages Are Associated with Poor Prognosis in Pancreatic Ductal Adenocarcinoma Patients
por: Yang, Xiaobao, et al.
Publicado: (2023)

Correction to: Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1
por: Okła, Karolina, et al.
Publicado: (2020)

CD72/CD100 and PD-1/PD-L1 markers are increased on T and B cells in HIV-1(+) viremic individuals, and CD72/CD100 axis is correlated with T-cell exhaustion
por: Correa-Rocha, Rafael, et al.
Publicado: (2018)

CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer
por: Cao, Lu, et al.
Publicado: (2022)

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
por: Zuazo, Miren, et al.
Publicado: (2019)

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
por: Zuazo, Miren, et al.
Publicado: (2020)

Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma
por: Saber, Manal Mohamed
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l8cprbbbm0tqpd1lets9c0kpgp